As a locally owned and operated business, 490 BioTech has worked closely with the city of Knoxville to maintain the highest standards for quality. We are proud to have been showcased as a success story for transitioning this exciting technology from our lab to yours.
Through years of academic research, 490 BioTech’s core technology has been developed and validated by research staff at the University of Tennessee, Knoxville. We look forward to putting our success to work in your lab as well.
490 BioTech is pleased to announce the acquisition of a Phase II SBIR award from the National Institutes of Health, National Institute of General Medical Sciences for the development of new high-throughput drug discovery screens
490 BioTech is pleased to announce a Phase II STTR award from the National Institutes of Health, National Institute of General Medical Sciences, that will enable the development of novel in vitro cellular and in
490 BioTech is proud to announce that Funakoshi Co., Ltd. has joined our distributor network to serve our research clientele in Japan.
SouthFound Media recently interviewed Dan Close, 490 BioTech’s Chief Science Officer, to discuss our autobioluminescent technology and the newest research we are pursuing. SouthFound specializes in helping Southern startups and entrepreneurs get focused, get funding,
490 BioTech will be speaking at the SOT 56th Annual Meeting and ToxExpo in Baltimore, Maryland from March 12-16, 2017. This year’s meeting, like its predecessors, is designed to provide you with access to cutting-edge
490 BioTech is pleased to announce distributor partnerships with Applied StemCell (USA, Japan), Proteigene (European Union, United Kingdom), and BioAspect Services About Applied StemCell: “Applied StemCell Inc. (ASC) is a fast growing biotechnology company headquartered
490 BioTech went to space on-board the SpaceX Falcon 9 rocket for the 14th resupply mission to the International Space Station on 4:30 p.m. EDT, Monday, April 2nd. Read all about our autobioluminescent cell lines
As a locally owned and operated business, 490 BioTech has worked closely with the city of Knoxville to maintain the highest standards for quality. We are proud to have been showcased as a success story for transitioning this exciting technology from our lab to yours.
Through years of academic research, 490 BioTech’s core technology has been developed and validated by research staff at the University of Tennessee, Knoxville. We look forward to putting our success to work in your lab as well.
490 BioTech is pleased to announce the acquisition of a Phase II SBIR award from the National Institutes of Health, National Institute of General Medical Sciences for the development of new high-throughput drug discovery screens
490 BioTech is pleased to announce a Phase II STTR award from the National Institutes of Health, National Institute of General Medical Sciences, that will enable the development of novel in vitro cellular and in
490 BioTech is proud to announce that Funakoshi Co., Ltd. has joined our distributor network to serve our research clientele in Japan.
SouthFound Media recently interviewed Dan Close, 490 BioTech’s Chief Science Officer, to discuss our autobioluminescent technology and the newest research we are pursuing. SouthFound specializes in helping Southern startups and entrepreneurs get focused, get funding,
490 BioTech will be speaking at the SOT 56th Annual Meeting and ToxExpo in Baltimore, Maryland from March 12-16, 2017. This year’s meeting, like its predecessors, is designed to provide you with access to cutting-edge
490 BioTech is pleased to announce distributor partnerships with Applied StemCell (USA, Japan), Proteigene (European Union, United Kingdom), and BioAspect Services About Applied StemCell: “Applied StemCell Inc. (ASC) is a fast growing biotechnology company headquartered
490 BioTech went to space on-board the SpaceX Falcon 9 rocket for the 14th resupply mission to the International Space Station on 4:30 p.m. EDT, Monday, April 2nd. Read all about our autobioluminescent cell lines
As a locally owned and operated business, 490 BioTech has worked closely with the city of Knoxville to maintain the highest standards for quality. We are proud to have been showcased as a success story for transitioning this exciting technology from our lab to yours.
Through years of academic research, 490 BioTech’s core technology has been developed and validated by research staff at the University of Tennessee, Knoxville. We look forward to putting our success to work in your lab as well.
490 BioTech is pleased to announce the acquisition of a Phase II SBIR award from the National Institutes of Health, National Institute of General Medical Sciences for the development of new high-throughput drug discovery screens
490 BioTech is pleased to announce a Phase II STTR award from the National Institutes of Health, National Institute of General Medical Sciences, that will enable the development of novel in vitro cellular and in
490 BioTech is proud to announce that Funakoshi Co., Ltd. has joined our distributor network to serve our research clientele in Japan.
SouthFound Media recently interviewed Dan Close, 490 BioTech’s Chief Science Officer, to discuss our autobioluminescent technology and the newest research we are pursuing. SouthFound specializes in helping Southern startups and entrepreneurs get focused, get funding,
490 BioTech will be speaking at the SOT 56th Annual Meeting and ToxExpo in Baltimore, Maryland from March 12-16, 2017. This year’s meeting, like its predecessors, is designed to provide you with access to cutting-edge
490 BioTech is pleased to announce distributor partnerships with Applied StemCell (USA, Japan), Proteigene (European Union, United Kingdom), and BioAspect Services About Applied StemCell: “Applied StemCell Inc. (ASC) is a fast growing biotechnology company headquartered
490 BioTech went to space on-board the SpaceX Falcon 9 rocket for the 14th resupply mission to the International Space Station on 4:30 p.m. EDT, Monday, April 2nd. Read all about our autobioluminescent cell lines
